Table 1 Characteristics of two study groups at the start of the current study
From: Control of Graves’ hyperthyroidism with very long-term methimazole treatment: a clinical trial
Variables | Continued MMI (n = 27) | Discontinued MMI (n = 32) |
|---|---|---|
Age, year | 53.1 ± 19.8 | 49.7 ± 12.4 |
Female, n (%) | 19 (70) | 22 (69) |
High school diploma, n (%) | 11 (41) | 12 (38) |
Goiter gradea, n (%) | ||
0 or 1 | 9 (33) | 10 (31) |
2 | 18 (67) | 22 (69) |
Current smoking, n (%) | 4 (15) | 5 (16) |
Ophthalmopathy, n (%) | 4 (15) | 5 (16) |
fT4, pmol/L | 16.1 ± 2.4 | 15.8 ± 2.6 |
T3, ng/dL | 125 ± 21 | 132 ± 26 |
TSH, mIU/L | 3.0 ± 0.6 | 2.9 ± 1.2 |
TRAb, IU/Lb | 1.3 ± 0.6 | 1.1 ± 0.7 |
MMI dose, mg/day | 3.4 ± 1.1 | 3.8 ± 1.2 |
Duration of MMI therapy, years‡ | 15.6 ± 1.9 | 12.8 ± 4.0 |
Comorbiditiesc, n (%) | 7 (26) | 9 (28) |